Greater absolute benefit with PCSK9 inhibition in diabetes patients - PACE-CME

Greater absolute benefit with PCSK inhibition in diabetes patients

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Finerenone does not alter vascular stiffness in patients with T2D and CKD
Finerenone does not alter vascular stiffness in patients with T2D and CKD
ESC Heart Failure 2025
Finerenone does not alter vascular stiffness in patients with T2D and CKD
- Atsushi Tanaka, MD, PhD
Is GLP-1RA use harmful or safe in patients with HFrEF and obesity?
Is GLP-1RA use harmful or safe in patients with HFrEF and obesity?
ESC Heart Failure 2025
Is GLP-1RA use harmful or safe in patients with HFrEF and obesity?
- Varun Sundaram, MD, PhD
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
ACC.25
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
- Marc Bonaca, MD
Perspectives on CKM syndrome
Perspectives on CKM syndrome
AHA 2024
Perspectives on CKM syndrome
- Javed Butler, MD